The 4th Xinyuanli Forum
4month1day-2On the day, the Fourth New Original Power Forum was successfully held in Hangzhou, Zhejiang Province. The New Original Power Forum was initiated by Dr. Yu Guoliang, the founder of the New Original Power Industrial Cluster. Each session has always adhered to the mission of empowering the innovative upgrading of China's biopharmaceutical industry, placing discussions on science, technology, and industry within the broad context of society, environment, and humanities. It brings together top scientists, entrepreneurs, and investors from the global biopharmaceutical field for in-depth discussions and exchanges.
As a highly influential life science industry conference in the industry, this year's conference lasted for two days, with an unprecedented scale of forums, attracting nearly a thousand participants online and offline.4month1The event features keynote speeches and forums, presented by Nobel laureatesBruce Beutler,DEFTAThe original patriarch and others unfolded,4month2Three parallel sub-forums on the same day, coveringRNATechnology, synthetic biology,FDANew policy,CGTandCXOFive major topics, with top industry guests discussing hot topics together.
Frost & SullivanFrost & SullivanMao Hua, Partner and Managing Director of Frost & Sullivan's Greater China Region, was invited to attend the conference and delivered a presentation on 'ChinaCXODelivered a speech on "Market Current Situation and Development Trends".
Partner and Managing Director of Frost & Sullivan Greater China Region fattening
Mao Hua pointed out, entrustCXOhas become an important path for pharmaceutical companies in drug research and development and production, capable of enhancing R&D efficiency, reducing costs, and promoting technological iteration. Both large pharmaceutical companies and startups can utilizeCXOBenefit from the high-quality services provided.
Data shows, ChinaCRO companyMarket scale has shifted from2017year43USD billion growth to2021year99billions, expected to2025The market size will grow to242billions of dollars; while ChinaCDMO companyMarket scale is determined by2017year2USD billion growth to2021year73billions, expected to2025This number will grow to244billion dollars. chinaCRO companyandCDMO companyService providers are playing an increasingly important role in the global market, relying on advantages such as talent, cost, and capital, with their share in the global market steadily increasing.
According to a study by Frost & Sullivan, segmented by clinical stage, in ChinaCRO firmIn the market, with the acceleration of the domestic innovative drug market andCRO companyAccelerated overseas business expansion of the company, drug discoveryCRO companyIt has developed most rapidly in recent years. However, in order for more Chinese innovative drugs to go global through self-development, Domestic clinical trialsCRO firmThe company will continuously enhance its capabilities, enter the global market, and is expected to conduct future clinicalCRO companyThe market scale will grow rapidly at the highest rate.
In the field of small molecule drugs, the success rate of developing new molecular entity drugs is low, the development difficulty is high, market competition tends to be fierce, and pharmaceutical companies tend toCDMO companyCooperation enhances efficiency and reduces product process development costs. Small moleculesCDMO companyContinuously provide services with high added value to meet the changing needs of drug R & D and production, targeting raw materials with high upstream and downstream technical barriersAPIPenetration at the formulation end continues to grow, and its market size continues to expand. 2017Year to2021The annual compound average growth rate exceeds32%, is expected to arrive2025Year, Chinese small moleculesCDMOThe market scale will exceed1,1001000 million RMB2021Year-end2025Annual compound average annual growth rate is nearly37%.
"In the biopharmaceutical field, the rapid development of the domestic biopharmaceutical market and the increase in overseas orders have driven the growth of China's biopharmaceuticalCDMO companyRapid rise. ” Mao Hua further explained that, on one hand, the Chinese biopharmaceutical market is growing rapidly, accounting for a continuous rise in the global pharmaceutical market share, which has driven up the demand for outsourcing services for biopharmaceutical research and development and production. On the other hand, the National Medical Products Administration's Center for Drug Evaluation (CDE) on2017Year-end2021Biopharmaceutical innovation drugs accepted during the yearINDThe surge in volume has continued to drive up the interest in innovative biopharmaceutical research and development, which has also led toCDMO companyThe demand is constantly growing, 2017Year to2021In [year], China's biopharmaceuticalsCDMO companyThe compound annual growth rate of the market scale exceeds52%, is expected to arrive2025In [year], the market size will reach4681000 million RMB.
atCGTfield CGTThe R&D and production barriers of products are high, and they rely more on outsourced R&D and production process services than traditional drugs. Moreover, the R&D costs of products are much higher than those of traditional drugs. R&D enterprises have a strong willingness to reduce costs and tend to entrust tasks.CDMO companyCooperate. R&D enterprises andCDMO companyGrow together, driveCGTThe clinical progress of the product effectively reduces R&D costs. ChinaCGT CDMOThe market scale is2017year7RMB 10 billion, an increase of2021year18100 billion RMB, expected by2025In [year], the market size will reach961000 million RMB2021Year-end2025The annual compound average growth rate exceeds50%.
Mao Hua believes that the futureCXOThe following development trends will be presented: 1)CXOEnterprises are extending vertically along the drug R&D industry chain to enhance customer stickiness and achieve a diversion effect;2)CXOLeading enterprises have started the pace of global expansion, further absorbing orders from home and abroad;3small and medium-sizedCXOEnterprises choose to deeply cultivate niche markets, strive to build distinctive and differentiated technological advantages, and seek development space in areas with technological strengths;4)CXOWhile the industry develops endogenously, it extends its industrial chain and optimizes strategic layout through external acquisitions and mergers to expand business scope and capacity.
About Frost & Sullivan's Healthcare Practice
The Healthcare Practice of Frost & Sullivan has professional analytical capabilities and extensive project experience in the life sciences sector. Leveraging Frost & Sullivan's global think tank resources and cross-industry business development platform in Greater China, Frost & Sullivan Healthcare has unique core advantages in healthcare industry investment and financing services. Frost & Sullivan Healthcare has a wide range of corporate clients in China, and in the past20In the year, a vast customer network was established, and a wealth of project experience in various medical sub-fields was accumulated.
Project types include Knowledge Center projects (in-depth content, promotional activities).Pre-IPO financingprojectDCF modelValuation, Business Plan Services),IPO listingWe provide listed projects (industry consulting, clinical audits, fundraising and investment writing), market research, market value management, and strategic consulting. We also cooperate with well-known domestic and international information platforms and investment and financing institutions to offer one-stop solutions for enterprises in specialized sub-sectors such as pharmaceuticals and medical devices. Our services have received wide attention from investors.
